Immuneering Shares Are Trading Higher. The Company Yesterday Announced That the First Patient Has Been Dosed in Its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors With RAF or RAS Mutations
Immuneering股票交易价格走高。该公司昨天宣布，在 IMM-6-415 的 1/2a 期试验中，第一位患者已服药，用于治疗带有 RAF 或 RAS 突变的晚期实体瘤